JOUNCE THERAPEUTICS INC's ticker is JNCE and the CUSIP is 481116101. A total of 80 filers reported holding JOUNCE THERAPEUTICS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 0.7%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2019 | $243,000 | +84.1% | 39,252 | 0.0% | 0.00% | – |
| Q4 2018 | $132,000 | -71.9% | 39,252 | -45.8% | 0.00% | – |
| Q3 2018 | $470,000 | +68.5% | 72,356 | +98.6% | 0.00% | – |
| Q2 2018 | $279,000 | -51.1% | 36,438 | +42.7% | 0.00% | -100.0% |
| Q1 2018 | $571,000 | +75.2% | 25,542 | 0.0% | 0.00% | – |
| Q4 2017 | $326,000 | +30.4% | 25,542 | +59.3% | 0.00% | – |
| Q3 2017 | $250,000 | +58.2% | 16,035 | +42.8% | 0.00% | – |
| Q2 2017 | $158,000 | -19.0% | 11,231 | +26.4% | 0.00% | – |
| Q1 2017 | $195,000 | – | 8,884 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| TRV GP II, LLC | 2,697,829 | $20,045,000 | 88.84% |
| TRV GP III, LLC | 3,048,780 | $22,652,000 | 4.30% |
| Logos Global Management LP | 2,000,000 | $14,860,000 | 1.07% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,559 | $1,550,000 | 0.88% |
| PFM Health Sciences, LP | 3,848,822 | $28,597,000 | 0.84% |
| Yorktown Management & Research Co Inc | 113,200 | $841,000 | 0.63% |
| Moloney Securities Asset Management, LLC | 282,250 | $2,097,000 | 0.38% |
| PATHWAY CAPITAL MANAGEMENT, LP | 84,763 | $630,000 | 0.30% |
| Sofinnova Investments, Inc. | 637,347 | $4,735,000 | 0.28% |
| Omega Fund Management, LLC | 275,513 | $2,047,000 | 0.23% |